Hypereosinophilic syndrome: Case series and review of the literature
Abstract
Abstract
Hypereosinophilic Syndrome (HES) is caused by the uncontrolled proliferation of eosinophils generally associated with conditions such as allergic reactions or parasitic infections. This syndrome is characterized by excessive eosinophil production (>1500/mm3) that persists for more than six months and cannot be explained by secondary causes. HES symptoms can affect different body organs, and usually, nonspecific symptoms include fever, malaise, fatigue, rash, shortness of breath, and myalgia.
HES is a rare disease with multiorgan involvement, including the skin, joints, kidneys, vascular system, gastrointestinal tract, cardiac and pulmonary systems. The main feature of this disease is that overproduced eosinophils accumulate in organs and cause organ damage. Cardiac involvement plays a critical role in determining morbidity and mortality, and cardiac and large vessel thrombosis with severe clinical manifestations can also be observed.
Treatment aims to reduce the absolute eosinophil count, improve symptoms, and prevent disease progression. Pharmacologic therapy aims to maintain targeted eosinophil levels below 1.5 x 10^9/L (1500 cells/mcL) to reduce the symptoms of eosinophilic disease and prevent organ damage. Furthermore, indications for emergency treatment should be rapidly assessed and initiated promptly in appropriate patients.
This paper will discuss the diagnosis, clinical manifestations, treatment modalities, and management challenges of HES in detail through two rare case examples.
Keywords
hypereosinophilia, eosinophil, hypereosinophilic syndrome
Supporting Institution
there isn't supporting institution
Project Number
1
Ethical Statement
ethical rules have been followed
References
- Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 2009;60:293-306.
- Suı T, Li Q, Geng L, Xu X, Li Y. A Case of Hypereosinophilic Syndrome Presenting with Multiorgan Thromboses Associated with Intestinal Obstruction. Turk J Haematol. 2013 Sep; 30(3): 311–314.
- Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45-9.
- Demirci NY, Kaplan M, Taçoy G, Türktaş H. Hypereosinophilic Syndrome Diagnosed with Acute Coronary Syndrome. Respir Case Rep 2017;6(3): 157-160.
- Kikuchi K, Minami K, Miyakawa H, Ishibashi M. Portal vein thrombosis in hypereosinophilic syndrome. Am J Gastroenterol. 2002;97:1274–1275.
- Rothenberg ME. Eosinophilia. New Engl J Med 1998;338:1592–1600.
- Pardanani A, Patnaik MM, Tefferi A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133:468–492.
- Tefferi A, Gotlib J, Pardanani A.Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. Mayo Clin Proc 2010; 85: 158 - 164.
- Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–2779.
- Keren M, Aksu K, Çiftci E, Kurt E. Lung, skin and heart involvement in a case with hypereosinophilic syndrome. Asthma Allergy Immunol 2011;9:44-5.